<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124353">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01877473</url>
  </required_header>
  <id_info>
    <org_study_id>VHS 12.0031</org_study_id>
    <nct_id>NCT01877473</nct_id>
  </id_info>
  <brief_title>Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valley Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Long Island Jewish Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State Research Institute of Circulation Pathology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Valley Health System</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that by facilitating reverse atrial remodeling with
      maintenance of sinus rhythm in the weeks preceding ablation makes it feasible to perform a
      simple pulmonary vein isolation (PVI) with results equivalent or superior to more complex
      atrial ablation for  patients with persistent AF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is the most common cardiac disorder currently affecting 2.3 million
      U.S. adults with an expected increase in incidence to 5.6 million by the year 2050.
      Randomized clinical trials have shown that ablation was superior to antiarrhythmic drug
      (AAD) in maintaining sinus rhythm among patients with symptomatic predominantly paroxysmal
      AF. However the results for catheter ablation of persistent AF is much lower and more
      variable, ranging between 20-80%. Moreover there is no agreed-upon standard ablation
      approach. Prior studies suggest that pulmonary vein isolation (PVI) alone has an
      unacceptably low success rate so most laboratories supplement this approach with additional
      lesion sets. These include complex atrial fractionated electrograms (&quot;CAFÃ‰&quot;), autonomic
      denervation, and linear left atrial ablation at the roof and mitral isthmus, in an empirical
      manner or stepwise approach.  However, these strategies are time consuming and prone to
      proarrhythmia, namely post-ablation atrial tachycardias which can occur with an incidence
      ranging from &lt; 5 to 50%.

      The lower efficacy of PVI alone in persistent AF has been attributed to adverse electrical,
      molecular, and structural remodeling of the atria. Collectively, atrial remodeling decreases
      conduction velocity and the effective refractory period, and results in a shortened atrial
      wavelength, which increases the number and stability of reentrant wavelets. This can cause
      persistence of AF independent of a focal discharge. Standard PVI addresses the &quot;focal
      discharge&quot; or trigger from the PVs that initiates AF but not necessarily the underlying
      atrial substrate.

      Based on these concepts, we hypothesized that successful atrial reverse remodeling by
      temporary AAD therapy would facilitate the performance of PVI alone in patients with
      persistent AF. The utilization of reverse remodeling to enhance the efficiency, efficacy and
      safety of ablation of AF has not been tested in a randomized clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Freedom of atrial fibrillation/flutter</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Reverse remodeling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pretreatment with dofetilide or sotalol and restoration of sinus rhythm followed by PVI only ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PVI ablation with additional CFAE and/or linear LA ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <arm_group_label>Reverse remodeling</arm_group_label>
    <arm_group_label>Standard ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic persistent AF

          -  Failure of class I antiarrhythmic drug or amiodarone to control AF

        Exclusion Criteria:

          -  Previous proarrhythmia to class III AAD including excessive QT prolongation or
             torsade-de-pointes

          -  Previous AF ablation procedure

          -  Congestive heart failure (NYHA III-IV functional class)

          -  Left ventricle ejection fraction less than 35%

          -  Left atrial diameter &gt;55 mm

          -  Unwillingness to participate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan S Steinberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Valley Health System/Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan S Steinberg, MD</last_name>
    <phone>212-432-7837</phone>
    <email>jss7@columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jagmeet Singh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jagmeet Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DeAnna Kearney, RN</last_name>
      <phone>201-432-7837</phone>
      <email>dkearne@valleyhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Hospital</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Slotwiner, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Slotwiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Institute of Circulation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny Pokushalov, MD</last_name>
    </contact>
    <investigator>
      <last_name>Evgeny Pokushalov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 10, 2013</lastchanged_date>
  <firstreceived_date>May 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Valley Health System</investigator_affiliation>
    <investigator_full_name>Jonathan Steinberg,MD</investigator_full_name>
    <investigator_title>Director, Arrhythmia Institute</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>persistent AF</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>duration of 7 days to one year</keyword>
  <keyword>with symptoms and failure of at least one antiarrhythmic drug</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
